SCHEMBL1715565

SCHEMBL1715565

COc1ccc(CNc2ccccc2C(=O)O)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.57
POLB P06746 1/20 0.57
HPGD P15428 1/20 0.57
HSD17B10 Q99714 1/20 0.57
CTDSP1 Q9GZU7 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
PLK1 P53350 1/20 0.52
HDAC1 Q13547 1/20 0.50
KDM4E B2RXH2 4/20 0.49
ASPH Q12797 3/20 0.49
KDM8 Q8N371 3/20 0.49
RIOX2 Q8IUF8 2/20 0.49
NAMPT P43490 1/20 0.49
KDM4C Q9H3R0 3/20 0.48
KDM6B O15054 1/20 0.48
KDM4A O75164 1/20 0.48
KDM4D Q6B0I6 1/20 0.48
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1715301 0.84 NPC1 (0.50) L3MBTL1HDAC1NAMPTKDM1AMAOA
SCHEMBL5627204 0.81 ALDH1A1 (0.52) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL1505239 0.80 ALDH1A1 (0.68) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL12461648 0.79 HDAC1 (0.42) L3MBTL1HDAC1KDM4ENAMPTKDM1A
SCHEMBL10322346 0.78 KDM4E (0.56) POLBHDAC1KDM4EASPHKDM8
SCHEMBL10084236 0.77 KMT2A (0.69) ALDH1A1POLBKDM4EMEN1KMT2A
SCHEMBL5900491 0.77 HDAC1 (0.46) POLBHDAC1SCDMAPK8
SCHEMBL1715269 0.77 HDAC1 (0.44) L3MBTL1HDAC1NAMPTMEN1KMT2A
SCHEMBL1037851 0.77 HDAC1 (0.46) POLBHDAC1SCDTAS2R14
SCHEMBL1039583 0.76 RXFP1 (0.68) NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN claimed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 ALDH1A1 804/4885POLB 1532/4885HPGD 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.